Compare XRX & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRX | CNTN |
|---|---|---|
| Founded | 1906 | 2017 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.6M | 184.2M |
| IPO Year | 2019 | 2022 |
| Metric | XRX | CNTN |
|---|---|---|
| Price | $1.31 | $3.26 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 3.3M | 462.2K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.84% | N/A |
| EPS Growth | ★ 23.26 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $117,000,000.00 | N/A |
| Revenue This Year | $8.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $3.07 |
| 52 Week High | $6.80 | $5.27 |
| Indicator | XRX | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 31.55 | 33.46 |
| Support Level | N/A | $3.15 |
| Resistance Level | $1.91 | $3.51 |
| Average True Range (ATR) | 0.10 | 0.31 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 7.57 | 14.44 |
Xerox Holdings Corp is an original equipment manufacturing and software company. Xerox operates in one segment--design, development, and sale of printing technology and related solutions--while deriving 60% of its revenue from the U.S. and 40% from international markets. The company is an OEM of multifunction printers, or MFPs (printers that can print, copy, and scan), focusing on large enterprise markets. Apart from equipment, the company provides post-sales services like managed print services help to bring smart servicing and efficiencies to how employers use their print/copy equipment. Xerox is attempting to enter new markets like digital print packaging solutions and printed electronics.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.